Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloStim In-Situ Vaccine for Solid Tumors
NCT01065441Phase 2Completed
- Sponsor
- Mirror Biologics, Inc.
- Start
- Dec 2010
- Primary completion
- Dec 2012
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allostim in solid tumor, sponsored by Mirror Biologics, Inc. Primary endpoint: Drug-related toxicity at 90 days. Started Dec 2010; status: completed.
02
Drugs
allostim
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT01065441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01065441.